Connect Biopharma Holdings Limited (CNTB)
Automate Your Wheel Strategy on CNTB
With Tiblio's Option Bot, you can configure your own wheel strategy including CNTB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CNTB
- Rev/Share 0.4716
- Book/Share 1.67
- PB 0.4498
- Debt/Equity 0.0019
- CurrentRatio 11.4584
- ROIC -0.192
- MktCap 41580422.0
- FreeCF/Share -0.4403
- PFCF -1.7112
- PE -2.663
- Debt/Assets 0.0018
- DivYield 0
- ROE -0.1537
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated st ructural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings …
Read More
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of …
Read More
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Published: March 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Strong balance sheet with cash runway into 2027 and through key clinical catalysts SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care …
Read More
About Connect Biopharma Holdings Limited (CNTB)
- IPO Date 2021-03-19
- Website https://www.connectbiopharm.com
- Industry Biotechnology
- CEO Dr. Barry D. Quart Pharm.D.
- Employees 62